U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07622121) titled 'Treatment of Chronic Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study' on May 27.
Brief Summary: The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Thyroid Eye Disease, TED
Intervention:
DRUG: MHB018A injection
MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)
DRUG: MHB018A injection Placebo
6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M...